A new meta-analysis published in Frontiers in Psychiatry suggests that fecal microbiota transplantation (FMT) can significantly reduce depressive symptoms, particularly when delivered through endoscopic or enema methods. The research, led by scientists from the Department of Nursing, Jiangsu Province Hospital of Chinese Medicine, and the Affiliated Hospital of Nanjing University of Chinese Medicine, also found that some participants experienced improvements in irritable bowel syndrome (IBS) symptoms.
The Growing Link Between Gut and Mental Health
Globally, more than 280 million people live with depression, and many do not achieve adequate relief from standard treatments such as medication or psychotherapy. Increasing evidence points to the microbiota–gut–brain axis, a complex communication network between gut microbes and the brain, as a key player in mood regulation. Alterations in gut composition have been linked to depression, suggesting that targeting gut microbes could offer a new therapeutic approach.
Furthermore, disorders of gut–brain interaction like IBS show high rates of psychiatric comorbidity, making microbiota-targeted interventions an appealing option for comprehensive symptom relief.
Analyzing Evidence Across Global Trials
As reported by medicalxpress, the study, titled “Clinical efficacy of fecal microbiota transplantation in alleviating depressive symptoms: a meta-analysis of randomized trials,” synthesized data from 12 randomized controlled trials conducted between 2019 and 2024. These trials, spanning China, Australia, Canada, Finland, and the United States, included 347 participants who received FMT and 334 controls who received placebo, autologous transplant, or standard medication.
FMT delivery methods varied across studies, including oral capsules, colonoscopy, gastroscopy, jejunum, rectal, and transendoscopic administration. Follow-up periods ranged from two weeks to 12 months, allowing researchers to compare short- and long-term outcomes.
Significant Reduction in Depressive Symptoms
Overall, the pooled results favored FMT over control interventions, showing a notable reduction in depressive symptoms. Both oral and direct gastrointestinal routes were effective, but endoscopic and enema delivery methods produced stronger results compared with capsules.
Short-term (up to 3 months) and intermediate-term (up to 6 months) follow-ups showed measurable improvement in mood, while long-term effects beyond six months did not reach statistical significance. This finding indicates that sustained benefits may require repeated or maintenance doses.
IBS Patients Show Greater Improvement
When the researchers conducted subgroup analyses, they observed a larger therapeutic effect among IBS patients compared with those with neurological or psychiatric disorders such as major depressive disorder, Parkinson’s disease, or progressive supranuclear palsy–Richardson’s syndrome. Importantly, publication bias across the studies appeared minimal, strengthening the reliability of the findings.
Promising Adjunctive Treatment for Depression
The authors concluded that fecal microbiota transplantation may serve as a valuable adjunctive therapy for depressive symptoms, particularly in patients with IBS. Endoscopic or enema delivery routes showed the most promise in improving outcomes.
However, they cautioned that the durability of these benefits beyond six months remains uncertain. Future research should include larger, longer-duration randomized trials and explore optimal dosing schedules to confirm and refine FMT’s role in treating mood disorders.
Summary
This comprehensive meta-analysis reinforces the growing understanding of the gut–brain connection in mental health. By restoring microbial balance, fecal microbiota transplantation offers a novel and potentially effective pathway to alleviate depression — especially for patients who do not respond to conventional therapies.